Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

28. April 2010 08:01 ET | Quelle: MDRNA, Inc.

MDRNA, Inc. Announces Combinations of UsiRNAs in Proprietary DiLA2 Delivery Technology Show Improved Efficacy in Bladder Cancer Model

BOTHELL, WA--(Marketwire - April 28, 2010) - MDRNA, Inc. (NASDAQ: MRNA), a leading RNAi-based drug discovery and development company, today reported data demonstrating greater efficacy in tumor...
19. April 2010 08:01 ET | Quelle: MDRNA, Inc.

MDRNA, Inc. Announces Patent Allowance Covering siRNA and Delivery Systems With Therapeutic Potential in Multiple Inflammatory Diseases

BOTHELL, WA--(Marketwire - April 19, 2010) - MDRNA, Inc. (NASDAQ: MRNA), a leading RNAi-based drug discovery and development company, today announced that the Intellectual Property Office of New...
12. April 2010 08:01 ET | Quelle: MDRNA, Inc.

MDRNA, Inc. Announces Patent Allowance Covering Intranasal Formulations for Y2-Receptor Agonists

BOTHELL, WA--(Marketwire - April 12, 2010) - MDRNA, Inc. (NASDAQ: MRNA), a leading RNA interference (RNAi)-based drug discovery and development company, today announced that the U.S. Patent and...
05. April 2010 08:01 ET | Quelle: MDRNA, Inc.

MDRNA, Inc. Announces Research Study With Pfizer

BOTHELL, WA--(Marketwire - April 5, 2010) - MDRNA, Inc. (NASDAQ: MRNA), a leading RNAi-based drug discovery and development company, today announced a study effort with Pfizer (NYSE:...
02. April 2010 08:00 ET | Quelle: MDRNA, Inc.

MDRNA, Inc. Complies With NASDAQ Marketplace Rule 5250(b)(2)

BOTHELL, WA--(Marketwire - April 2, 2010) - MDRNA, Inc. (NASDAQ: MRNA), a leading RNAi-based drug discovery and development company, today announced that the Company's independent registered public...
01. April 2010 07:00 ET | Quelle: MDRNA, Inc.

MDRNA, Inc. Acquires Cequent Pharmaceuticals

BOTHELL, WA and CAMBRIDGE, MA--(Marketwire - April 1, 2010) - MDRNA, Inc. (NASDAQ: MRNA), a leading RNAi-based drug discovery and development company, and Cequent Pharmaceuticals, a pioneer in...
29. März 2010 08:01 ET | Quelle: MDRNA, Inc.

MDRNA, Inc. Announces Patent Allowance Covering Methods for Cell Specific Delivery of siRNAs

BOTHELL, WA--(Marketwire - March 29, 2010) - MDRNA, Inc. (NASDAQ: MRNA), a leading RNAi-based drug discovery and development company, today announced that the U.S. Patent and Trademark Office...
23. März 2010 16:05 ET | Quelle: MDRNA, Inc.

MDRNA, Inc. Acquires Bridged Nucleic Acid (BNA) Patents to Broaden Its RNAi-Drug Discovery Platform

BOTHELL, WA--(Marketwire - March 23, 2010) - MDRNA, Inc. (NASDAQ: MRNA), a leading RNAi-based drug discovery and development company, announced today that it has acquired intellectual property...
23. März 2010 16:02 ET | Quelle: MDRNA, Inc.

MDRNA, Inc. Announces Fourth Quarter and Full Year 2009 Financial Results

BOTHELL, WA--(Marketwire - March 23, 2010) - MDRNA, Inc. (NASDAQ: MRNA), a leading RNAi-based drug discovery and development company, today reported financial results for the fourth quarter and year...
16. März 2010 08:30 ET | Quelle: MDRNA, Inc.

MDRNA, Inc. to Report Fourth Quarter and Year-End 2009 Results on March 23, 2010 at 4:30 p.m. Eastern Time

BOTHELL, WA--(Marketwire - March 16, 2010) - MDRNA, Inc. -- (NASDAQ: MRNA), a leading RNAi-based drug discovery and development company, today announced that it will host a conference call...

Vorherige Seite